60 yr old female known SHTN came with dyspnea for 1 day and pedal edema for 1 week

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Searching PubMed

"heart failure" AND "hypertension" AND "HFpEF"

Loading Image

Reading File

Finding Sources

I now have excellent content from Harrison's, Robbins, Clinical Echocardiography, and Comprehensive Clinical Nephrology. Let me compile a thorough clinical response.

Clinical Case Analysis: 60F with Known Hypertension, Dyspnea (1 day) + Pedal Edema (1 week)

Most Likely Diagnosis

Acute Decompensated Heart Failure (ADHF) secondary to Hypertensive Heart Disease

This is the classic presentation. Long-standing systemic hypertension leads to left ventricular pressure overload, which drives LV hypertrophy and ultimately diastolic and/or systolic dysfunction.

Pathophysiology (Why This Happens)

Hypertension imposes chronic pressure overload on the left ventricle. The LV responds with concentric hypertrophy - an adaptive mechanism that has limits. Per Robbins Pathology:

"Persistent hypertension can eventually culminate in dysfunction, cardiac dilation, CHF, and sudden death... the hypertrophic myocytes fail to contract efficiently, possibly due to structural abnormalities in newly assembled sarcomeres and because the vascular supply is inadequate to meet the demands of the increased muscle mass."

There are two pathways to HF in hypertension, important to distinguish:

Feature	HFpEF (Diastolic Dysfunction)	HFrEF (Systolic Dysfunction)
EF	≥50% (preserved)	≤40% (reduced)
LV size	Concentric hypertrophy, small cavity	Dilated
Mechanism	Impaired early diastolic filling → elevated LA pressure → pulmonary venous HTN	Loss of contractility
Common in	Early/mid-stage hypertensive disease, older women	Late-stage or coexistent CAD

This patient - older female with hypertension - has a very high probability of HFpEF. As the echocardiography textbook notes:

"Early in the disease course, pathologic hypertrophy is associated with impaired early diastolic filling. Impaired ventricular filling leads to elevated LA pressures and pulmonary venous hypertension, resulting in dyspnea."

The pedal edema (1 week) reflects chronic venous congestion (right-sided/systemic); the acute dyspnea (1 day) reflects a new trigger causing rapid pulmonary decompensation.

Precipitants to Search For

Per Harrison's, the first principle of ADHF management is identifying the precipitating factor:

Non-adherence to antihypertensive medications or sodium restriction (most common)
Uncontrolled hypertension - a "hypertensive ADHF" phenotype (usually NOT volume-overloaded; responds to vasodilators)
Dietary salt excess
New arrhythmia (especially atrial fibrillation - common with LA enlargement from chronic HTN)
Coronary ischemia / ACS - must rule out
Infection / sepsis (increased cardiac demand)
NSAIDs or other nephrotoxic/fluid-retaining drugs
Pulmonary embolism
New valvular disease

Initial Evaluation

History:

Symptom progression, orthopnea, PND, weight gain
Medication compliance (antihypertensives, diuretics)
Dietary habits (salt intake)
Palpitations (arrhythmia?)
Chest pain (ACS?)

Examination:

BP (likely elevated - hypertensive ADHF), HR, SpO2, RR
JVP elevation
Bibasilar crackles
S3 gallop (volume-overloaded HFrEF) vs S4 (stiff/hypertrophic ventricle, HFpEF)
Pedal/pitting edema grade
Hepatomegaly, ascites (right heart congestion)
Signs of low output: cold extremities, narrow pulse pressure

Investigations:

Test	Purpose
ECG	LVH pattern (voltage criteria), arrhythmia, ischemia
Chest X-ray	Cardiomegaly, pulmonary vascular congestion, pleural effusions, Kerley B lines
Echocardiogram	Key test - EF (HFpEF vs HFrEF), LV wall thickness, diastolic function grading, valvular disease
BNP / NT-proBNP	Confirms HF diagnosis; elevated in both HFpEF and HFrEF; guides prognosis
CBC	Anemia as precipitant
Renal function + electrolytes	Baseline before diuretics; cardiorenal syndrome
Serum troponin	Rule out ACS as trigger
Blood glucose / HbA1c	Comorbidities
Thyroid function	Hypothyroid can precipitate decompensation
Urinalysis	Proteinuria (hypertensive nephropathy)

ADHF Phenotypes and Management (Harrison's Fig. 265-2)

This patient most likely fits the "Hypertensive ADHF" phenotype (top-left of figure):

Acute dyspnea, elevated BP, redistribution pulmonary edema (often NOT truly volume-overloaded)
Primary treatment: Vasodilators (reduce afterload rapidly) + supplemental O2
If volume-overloaded: IV diuretics

Acute Management

1. Oxygen / Ventilatory Support

Target SpO2 >94%
High-flow O2, consider non-invasive ventilation (CPAP/BiPAP) if severe hypoxia or respiratory distress - reduces preload and work of breathing

2. Vasodilators (Hypertensive ADHF - priority)

IV Nitroglycerine (sublingual first, then infusion) - reduces preload and afterload, relieves pulmonary congestion rapidly
IV Nitroprusside - more potent afterload reduction if BP very high

3. IV Loop Diuretics (if volume-overloaded)

Furosemide IV - rapid onset, natriuresis and venodilatation
Monitor urine output, daily weights, electrolytes
If refractory: add metolazone (sequential nephron blockade) - watch for hypokalemia

4. Monitor for Cardiorenal Syndrome

Per Harrison's: ~30% of ADHF patients have renal impairment at baseline. Worsening creatinine during diuresis requires hemodynamic reassessment.

Longer-Term Management (Post-Stabilization)

For HFpEF (likely in this patient)

Per Comprehensive Clinical Nephrology:

"BP lowering is commonly required in patients with HFpEF. If volume overload is present, diuretics will be required."

Guideline-directed therapy for HFpEF + HTN:

BP control to target (<130/80 mmHg)
Loop/thiazide diuretics for congestion control
SGLT2 inhibitors (empagliflozin/dapagliflozin) - now shown to reduce HF hospitalizations in HFpEF regardless of diabetes status (Harrison's 2025)
Mineralocorticoid receptor antagonists (spironolactone) - variable evidence, may reduce HF hospitalizations
Sacubitril/valsartan (ARNI) - emerging data in HFpEF, better evidence in HFrEF
GLP-1 agonists - newer data in obese HFpEF patients

For HFrEF (if EF is reduced)

Per Comprehensive Clinical Nephrology - the "4 pillars":

ACEi/ARB or ARNI (sacubitril/valsartan preferred)
Beta-blocker (carvedilol, bisoprolol, metoprolol succinate)
Mineralocorticoid receptor antagonist (spironolactone/eplerenone)
SGLT2 inhibitor

Avoid: Non-DHP calcium channel blockers (diltiazem, verapamil), alpha-blockers, moxonidine in HF

Red Flags Requiring Urgent Action

SpO2 <90% despite O2 → BiPAP / intubation
SBP <90 mmHg → cardiogenic shock protocol (inotropes, mechanical support)
ACS on ECG/troponin → urgent cardiology consult
New AF with fast ventricular rate → rate control / cardioversion
BUN >43 mg/dL + Cr >2.75 mg/dL + SBP <115 mmHg → worse prognosis, escalate monitoring

Summary

Aspect	Key Point
Likely diagnosis	Acute decompensated HF (hypertensive - probable HFpEF)
Mechanism	HTN → LVH → diastolic dysfunction → elevated LVEDP → pulmonary venous HTN
Priority investigations	ECG, CXR, Echo, BNP, troponin, renal function
Acute treatment	O2, IV nitroglycerin (vasodilator), IV furosemide
Disease-modifying (HFpEF)	BP control, SGLT2 inhibitor, diuretics, possibly spironolactone
Disease-modifying (HFrEF)	ARNI + BB + MRA + SGLT2i ("4 pillars")

Sources:

Harrison's Principles of Internal Medicine, 22e (2025) - ADHF chapter
Comprehensive Clinical Nephrology, 7th ed. - Hypertension in HF
Textbook of Clinical Echocardiography - Hypertensive heart disease & diastolic dysfunction
Robbins & Kumar Basic Pathology - Hypertensive heart disease pathology
Recent PubMed: Systematic review on HFpEF phenotyping in device trials (PMID 40857067, 2025) and meta-analysis on BP and pulse pressure in HF (PMID 39745404, 2025 JACC)

This is a shared conversation. Sign in to Orris to start your own chat.